Back to today’s briefing

Story perspectives

Ocugen and PulseSight Pioneering Breakthroughs in Eye Therapies

2/14/2025

26 4

Summary

Story summary

Ocugen, Inc. has reached a significant milestone by completing Phase 2 dosing of OCU410, a groundbreaking gene therapy targeting geographic atrophy, a debilitating eye condition impacting millions. This innovative treatment promises lasting effects from just one injection, potentially revolutionizing care. Simultaneously, PulseSight Therapeutics is making strides with PST-611, a non-viral therapy for dry AMD, fueled by fresh funding.

1 of 1

Story summary

Ocugen, Inc. has reached a significant milestone by completing Phase 2 dosing of OCU410, a groundbreaking gene therapy targeting geographic atrophy, a debilitating eye condition impacting millions. This innovative treatment promises lasting effects from just one injection, potentially revolutionizing care. Simultaneously, PulseSight Therapeutics is making strides with PST-611, a non-viral therapy for dry AMD, fueled by fresh funding.